Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus FALMINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus FALMINA.
ENOVID-E vs FALMINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
FALMINA (fictitious drug): 500 mg orally every 12 hours.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life 12-15 hours; in severe renal impairment (CrCl <30 mL/min) extends to 30-40 hours, requiring dose adjustment.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Primarily renal (85% unchanged drug, 10% as glucuronide conjugate); biliary/fecal 5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive